How a microbial expression update is driving biotech innovation
Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.
Ute Boronowsky
About
Ute Boronowsky obtained a PhD in plant biochemistry at the Ruhr-University Bochum in 1999. After her postdoc at UCLA, she moved to the biotech industry and worked in various sales and marketing positions. Since 2015, she works as a freelance science and marketing writer, translator, and journalist.
Articles by Ute Boronowsky
Biologics testing: The right time to move to new standards?
Discover the challenges facing biologics testing and how modern methods like NGS are revolutionizing quality control, ensuring safety and efficacy.
Complex innovative designs: tackling rare disease clinical trial challenges
Unlock the power of complex innovative designs to tackle rare disease clinical trial challenges efficiently.
Protein inhibitors: cracking the code of disease mechanisms
Explore how protein inhibitors revolutionize disease understanding, by unlocking the secrets of disease pathways.
Can we overcome the challenges of bispecific antibody production?
Thanks to their unique features, bispecific antibodies are the fastest-evolving class of biotherapeutics. However, the enormous clinical potential of their unconventional design is accompanied by equally large challenges. How can we ensure reliable production and quality control of therapeutic bispecific antibodies? Compared to monoclonal antibodies, bispecific antibodies (bsAbs) have two different binding areas that recognize […]
Drugging ‘undruggable’ targets: Are high-throughput proximity assays the answer?
Drug screening follows the funnel principle – the higher the number and diversity of compounds assayed, the better the chances to identify meaningful hits that turn into promising clinical candidates. Robust high throughput screening assays to monitor target activity are key to reaching this goal in a reasonable time. With low-hanging fruits already ticked off […]
ADVERTISEMENT
ADVERTISEMENT
20 years of BIOSPAIN – The evolution of an international biotech event
Becoming human: GMP-compliant supplements for cell therapy
From breast to bone: Refining metastasis drug discovery with a novel organ-on-a-chip device
Understanding invasive cancer progression and metastasis formation are among the core open questions in cancer research. However, the limitations of current models lead to high failure rates in drug development. An EU-funded consortium has designed an organ-on-a-chip approach that could deliver new insights. In metastasis, circulating tumor cells spontaneously shed from the primary site to […]
How efficient lab inventory management can become a driver for success
Lab inventory management is often not the first priority of biotech companies trying to stay ahead in a competitive environment. But according to a report released by the EU commission, the hidden costs of inefficient lab practices are estimated to exceed €10B every year. Novel lab inventory management solutions can thus reduce costs and push […]
How clinical trials benefit from decentralized solutions: A Nordic case study
Digitization is changing the way clinical trials are conducted. Spurred by the pandemic, decentralized clinical trials are on the rise, with clear benefits for clinicians and patients. Three Nordic companies have teamed up to analyze the effect of decentralized solutions for a clinical trial on neuropathic pain. With electronic devices available in most patient households […]
Transforming customer journeys, one step at a time: An interview with Mike Chen, CEO of ACROBiosystems
ADVERTISEMENT